FI1732548T4 - Viivästetysti lääkeainetta vapauttavien aminopyridiiniyhdisteiden käyttömenetelmät - Google Patents

Viivästetysti lääkeainetta vapauttavien aminopyridiiniyhdisteiden käyttömenetelmät Download PDF

Info

Publication number
FI1732548T4
FI1732548T4 FIEP05732613.4T FI05732613T FI1732548T4 FI 1732548 T4 FI1732548 T4 FI 1732548T4 FI 05732613 T FI05732613 T FI 05732613T FI 1732548 T4 FI1732548 T4 FI 1732548T4
Authority
FI
Finland
Prior art keywords
bid
jossa
koostumus
viivästetysti
päivässä
Prior art date
Application number
FIEP05732613.4T
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Inventor
Andrew Blight
Lawrence Marinucci
Ron Cohen
Original Assignee
Acorda Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35061389&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI1732548(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acorda Therapeutics Inc filed Critical Acorda Therapeutics Inc
Application granted granted Critical
Publication of FI1732548T4 publication Critical patent/FI1732548T4/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
FIEP05732613.4T 2004-04-09 2012-01-19 Viivästetysti lääkeainetta vapauttavien aminopyridiiniyhdisteiden käyttömenetelmät FI1732548T4 (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56089404P 2004-04-09 2004-04-09
US11/102,559 US8354437B2 (en) 2004-04-09 2005-04-08 Method of using sustained release aminopyridine compositions
PCT/US2005/012427 WO2005099701A2 (en) 2004-04-09 2005-04-11 Methods of using sustained release aminopyridine compositions

Publications (1)

Publication Number Publication Date
FI1732548T4 true FI1732548T4 (fi) 2023-11-30

Family

ID=35061389

Family Applications (2)

Application Number Title Priority Date Filing Date
FIEP05732613.4T FI1732548T4 (fi) 2004-04-09 2012-01-19 Viivästetysti lääkeainetta vapauttavien aminopyridiiniyhdisteiden käyttömenetelmät
FIC20130042C FIC20130042I1 (fi) 2004-04-09 2013-08-13 Fampridiini tai sen suola tai solvaatti

Family Applications After (1)

Application Number Title Priority Date Filing Date
FIC20130042C FIC20130042I1 (fi) 2004-04-09 2013-08-13 Fampridiini tai sen suola tai solvaatti

Country Status (21)

Country Link
US (13) US8354437B2 (OSRAM)
EP (5) EP1732548B2 (OSRAM)
JP (4) JP5736100B2 (OSRAM)
AT (1) ATE511841T1 (OSRAM)
AU (1) AU2005232732B2 (OSRAM)
CA (2) CA2870734C (OSRAM)
CY (4) CY1111754T1 (OSRAM)
DK (2) DK1732548T4 (OSRAM)
ES (2) ES2367707T5 (OSRAM)
FI (2) FI1732548T4 (OSRAM)
FR (1) FR13C0033I2 (OSRAM)
HR (2) HRP20110497T4 (OSRAM)
HU (1) HUE046320T2 (OSRAM)
LU (2) LU91933I2 (OSRAM)
ME (2) ME01836B (OSRAM)
MX (3) MX370434B (OSRAM)
PL (2) PL2377536T5 (OSRAM)
PT (2) PT2377536E (OSRAM)
RS (2) RS51808B2 (OSRAM)
SI (2) SI1732548T2 (OSRAM)
WO (1) WO2005099701A2 (OSRAM)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8007826B2 (en) * 2003-12-11 2011-08-30 Acorda Therapeutics, Inc. Sustained release aminopyridine composition
US8354437B2 (en) 2004-04-09 2013-01-15 Acorda Therapeutics, Inc. Method of using sustained release aminopyridine compositions
AU2013206188B2 (en) * 2005-09-23 2016-04-14 Acorda Therapeutics, Inc. Method, apparatus and software for identifying responders in a clinical environment
CN101827522A (zh) * 2008-09-10 2010-09-08 阿索尔达治疗股份有限公司 持续释放氨基吡啶组合物的使用方法
BRPI1000030A2 (pt) * 2009-02-11 2018-02-14 Acorda Therapeutics Inc métodos para tratar esclerose múltipla em um paciente, para aumentar a capacidade de caminhar, para tratar os sintomas da esclerose múltipla, e, composição.
JO3348B1 (ar) * 2009-08-11 2019-03-13 Acorda Therapeutics Inc استخدام 4- بايريدين امينو لتحسين الادراك العصبي و/او التلف النفسي لدى مرضى يعانون من نقص النُخاعين وغير ذلك من امراض الجهاز العصبي
TW201125562A (en) * 2009-09-04 2011-08-01 Acorda Therapeutics Inc Sustained release fampridine treatment in patients with multiple sclerosis
EP2995305B1 (en) 2011-01-28 2020-03-04 Acorda Therapeutics, Inc. Use of potassium channel blockers to treat cerebral palsy
US8924325B1 (en) * 2011-02-08 2014-12-30 Lockheed Martin Corporation Computerized target hostility determination and countermeasure
CA2840591A1 (en) 2011-06-30 2013-01-03 Biomarin Pharmaceuticals, Inc. Methods of administering 3,4-diaminopyridine
TWI592156B (zh) 2011-10-04 2017-07-21 艾可達醫療公司 使用胺基吡啶以治療與中風有關之感覺動作損傷之方法
EP3381455A1 (en) * 2012-02-13 2018-10-03 Acorda Therapeutics, Inc. Methods for treating an impairment in gait and/or balance in patients with multiple sclerosis using an aminopyridine
WO2014028387A1 (en) 2012-08-13 2014-02-20 Acorda Therapeutics, Inc. Methods for improving walking capacity in patients with multiple sclerosis using an aminopyridine
WO2014093475A1 (en) 2012-12-11 2014-06-19 Acorda Therapeutics, Inc. Methods for treating parkinson's disease using aminopyridines
DK2970101T4 (da) 2013-03-14 2025-11-17 Alkermes Pharma Ireland Ltd Pro-drugs af fumarater og deres anvendelse i behandling af forskellige sygdomme
WO2014151752A1 (en) * 2013-03-15 2014-09-25 University Of Rochester Composition and methods for the treatment of peripheral nerve injury
EP3243516A1 (en) 2013-04-15 2017-11-15 Acorda Therapeutics, Inc. Methods for treating sensorimotor impairments associated with certain types of stroke using aminopyridines
UA121323C2 (uk) 2015-02-08 2020-05-12 Алкермес Фарма Айрленд Лімітед Композиції на основі проліків монометилфумарату
RU2580837C1 (ru) * 2015-05-05 2016-04-10 Федеральное Государственное Автономное Образовательное Учреждение Высшего Профессионального Образования "Московский Физико-Технический Институт (Государственный Университет)" Кристаллогидрат 4-аминопиридина, способ его получения, фармацевтическая композиция и способ лечения и/или профилактики на её основе
US10172842B2 (en) 2015-09-11 2019-01-08 PharmaDax Inc. Sustained release oral dosage form containing dalfampridine
ES3008933T3 (en) 2015-09-29 2025-03-25 Merz Pharmaceuticals Llc Sustained release compositions of 4-aminopyridine
CA3059180C (en) 2017-04-06 2023-10-17 Acorda Therapeutics, Inc. Sustained release compositions of 4-aminopyridine

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1082804A (en) 1912-11-19 1913-12-30 Gerald G Griffin Confetti-machine.
US3065143A (en) 1960-04-19 1962-11-20 Richardson Merrell Inc Sustained release tablet
CH415963A (de) 1964-09-04 1966-06-30 Wander Ag Dr A Masse zur Herstellung von Tabletten mit protrahierter Wirkung
US3538214A (en) 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US4508715A (en) 1981-07-01 1985-04-02 University Of Georgia Research Foundation, Inc. Antagonism of central nervous system drugs by the administration of 4-aminopyridine alone or in combination with other drugs
US4386095A (en) 1982-02-22 1983-05-31 Cornell Research Foundation, Inc. Diaminopyridines to improve cognition
IE53703B1 (en) 1982-12-13 1989-01-18 Elan Corp Plc Drug delivery device
IE54286B1 (en) 1983-01-18 1989-08-16 Elan Corp Plc Drug delivery device
US4851230A (en) 1983-04-07 1989-07-25 Bristol-Myers Company Capsule shaped tablets
IE56459B1 (en) 1983-12-21 1991-08-14 Elan Corp Ltd Controlled absorption pharmaceutical formulation
US4894240A (en) 1983-12-22 1990-01-16 Elan Corporation Plc Controlled absorption diltiazem formulation for once-daily administration
IE56999B1 (en) 1983-12-22 1992-03-11 Elan Corp Plc Pharmaceutical formulation
US4562196A (en) 1984-04-06 1985-12-31 Nelson Research & Development 2,4-Diaminopyridine as a pharmacologic agent
JPS6124516A (ja) 1984-07-12 1986-02-03 Fujisawa Pharmaceut Co Ltd 持続性錠剤
US4812447A (en) 1985-10-22 1989-03-14 City Of Hope Method for the treatment of nervous system degeneration
US4760092A (en) 1985-10-29 1988-07-26 The Rockefeller University Treatment of demyelinating diseases
US4832957A (en) 1987-12-11 1989-05-23 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
IL86170A (en) 1987-05-01 1992-12-01 Elan Transdermal Ltd Preparations and compositions comprising nicotine for percutaneous administration
IE64726B1 (en) 1987-11-20 1995-08-23 Elan Corp Plc Pharmaceutical formulations for preventing drug tolerance
FI895821A7 (fi) 1988-12-07 1990-06-08 The Wellcome Foundation Ltd Farmaseuttisesti aktivisia CNS-yhdisteitä
US4948581A (en) 1989-02-17 1990-08-14 Dojin Iyaku-Kako Co., Ltd. Long acting diclofenac sodium preparation
IE82916B1 (en) 1990-11-02 2003-06-11 Elan Corp Plc Formulations and their use in the treatment of neurological diseases
TW200462B (OSRAM) 1990-09-27 1993-02-21 Hoechst Roussel Pharma
CA2085785C (en) 1992-12-18 2005-03-15 Robert R. Hansebout The use of 4-aminopyridine in the treatment of a neurological condition
DE4321030A1 (de) * 1993-06-24 1995-01-05 Bayer Ag 4-bicyclisch substituierte Dihydropyridine, Verfahren zu ihrer Herstellung und ihre Verwendung in Arzneimittel
US5451409A (en) 1993-11-22 1995-09-19 Rencher; William F. Sustained release matrix system using hydroxyethyl cellulose and hydroxypropyl cellulose polymer blends
KR100354702B1 (ko) 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
US5952357A (en) 1993-12-23 1999-09-14 Cornell Research Foundation, Inc. Treating diseases of the anterior horn cells
US6284473B1 (en) 1995-10-02 2001-09-04 Uab Research Foundation P-cresol sulfate, a component of urinary myelin basic protein-like material, as a correlate of multiple sclerosis status
US7179486B1 (en) 1997-04-01 2007-02-20 Nostrum Pharmaceuticals, Inc. Process for preparing sustained release tablets
US6288026B1 (en) 1999-02-24 2001-09-11 Heinrich Exner Process and composition for treating diseases with an oil-in-water emulsion
US6600399B1 (en) 2002-02-05 2003-07-29 Roland Pierre Trandafir Transducer motor/generator assembly
WO2004082684A1 (en) 2003-03-17 2004-09-30 Acorda Therapeutics Stable oral formulations of aminopyridines and uses thereof
EP1617844A4 (en) 2003-04-03 2009-07-22 Prana Biotechnology Ltd TREATMENT OF NEUROLOGICAL DISEASES
CA2534711A1 (en) 2003-08-01 2005-02-10 Medarex, Inc. Combination therapies for multiple sclerosis
US8007826B2 (en) 2003-12-11 2011-08-30 Acorda Therapeutics, Inc. Sustained release aminopyridine composition
US8354437B2 (en) 2004-04-09 2013-01-15 Acorda Therapeutics, Inc. Method of using sustained release aminopyridine compositions
EP1888056A4 (en) 2005-06-01 2008-09-03 Teva Pharma USE OF LADOSTIGIL FOR TREATING MULTIPLE SCLEROSIS
US20090150180A1 (en) 2005-09-23 2009-06-11 Ron Cohen Method, apparatus and solftware for identifying responders in clinical environment
TWM331106U (en) * 2007-11-12 2008-04-21 Syspotek Corp Solution counter with temperature sensor
CN101827522A (zh) 2008-09-10 2010-09-08 阿索尔达治疗股份有限公司 持续释放氨基吡啶组合物的使用方法
WO2010090730A1 (en) 2009-02-03 2010-08-12 Acorda Therapeutics, Inc. Method, apparatus and software for identifying responders in a clinical environment
BRPI1000030A2 (pt) 2009-02-11 2018-02-14 Acorda Therapeutics Inc métodos para tratar esclerose múltipla em um paciente, para aumentar a capacidade de caminhar, para tratar os sintomas da esclerose múltipla, e, composição.
JO3348B1 (ar) 2009-08-11 2019-03-13 Acorda Therapeutics Inc استخدام 4- بايريدين امينو لتحسين الادراك العصبي و/او التلف النفسي لدى مرضى يعانون من نقص النُخاعين وغير ذلك من امراض الجهاز العصبي
TW201125562A (en) 2009-09-04 2011-08-01 Acorda Therapeutics Inc Sustained release fampridine treatment in patients with multiple sclerosis
US10255905B2 (en) 2016-06-10 2019-04-09 Google Llc Predicting pronunciations with word stress

Also Published As

Publication number Publication date
AU2005232732B2 (en) 2011-05-12
JP2007532578A (ja) 2007-11-15
US20160199358A1 (en) 2016-07-14
RS51808B2 (sr) 2023-12-29
ES2746354T3 (es) 2020-03-05
US20110166187A1 (en) 2011-07-07
FR13C0033I2 (fr) 2015-11-20
EP2377536A1 (en) 2011-10-19
MXPA06011648A (es) 2008-10-31
DK2377536T4 (da) 2022-11-07
AU2005232732A1 (en) 2005-10-27
US20180200241A1 (en) 2018-07-19
LU92275I9 (OSRAM) 2019-01-03
US20170209422A1 (en) 2017-07-27
PT2377536E (pt) 2013-04-11
HRP20130424T4 (hr) 2022-10-28
EP2377536B1 (en) 2013-03-06
EP2460521B1 (en) 2019-06-12
ME01836B (me) 2014-12-20
US9925173B2 (en) 2018-03-27
US20120164078A1 (en) 2012-06-28
EP1732548B2 (en) 2023-08-30
HRP20130424T1 (en) 2013-06-30
PL1732548T5 (pl) 2024-11-04
ES2367707T3 (es) 2011-11-07
EP1732548A4 (en) 2009-06-03
US20150080436A1 (en) 2015-03-19
CY2013035I1 (el) 2020-05-29
HK1162971A1 (en) 2012-09-07
SI2377536T1 (sl) 2013-07-31
LU91933I2 (fr) 2013-01-18
PL2377536T3 (pl) 2013-08-30
US20120064007A1 (en) 2012-03-15
CA2562277A1 (en) 2005-10-27
CA2870734C (en) 2022-08-16
US20050228030A1 (en) 2005-10-13
MX370434B (es) 2019-12-13
WO2005099701A3 (en) 2006-03-23
RS51808B8 (sr) 2019-08-30
RS51808B (sr) 2011-12-31
EP3922248A1 (en) 2021-12-15
US20170071924A1 (en) 2017-03-16
PT1732548E (pt) 2011-09-16
FR13C0033I1 (fr) 2013-08-09
US20170273960A1 (en) 2017-09-28
WO2005099701A2 (en) 2005-10-27
SI1732548T1 (sl) 2011-09-30
PL1732548T4 (pl) 2012-03-30
CA2870734A1 (en) 2005-10-27
US20140039015A1 (en) 2014-02-06
PL2377536T5 (pl) 2023-03-06
EP1732548B9 (en) 2012-03-21
CY2024026I2 (el) 2025-03-28
MX2019015036A (es) 2020-02-24
HRP20110497T4 (hr) 2024-03-29
LU92275I2 (fr) 2015-09-03
SI2377536T2 (sl) 2022-11-30
US20110166188A1 (en) 2011-07-07
EP1732548A2 (en) 2006-12-20
FIC20130042I1 (fi) 2013-08-13
HRP20110497T1 (hr) 2011-08-31
JP5736100B2 (ja) 2015-06-17
JP5914626B2 (ja) 2016-05-11
JP2012188427A (ja) 2012-10-04
US8440703B2 (en) 2013-05-14
PL1732548T3 (pl) 2011-11-30
CA2562277C (en) 2015-01-27
EP2377536B2 (en) 2022-08-17
JP2015057451A (ja) 2015-03-26
CY1114073T1 (el) 2016-07-27
DK1732548T4 (da) 2023-11-20
SI1732548T2 (sl) 2024-02-29
RS53371B2 (sr) 2022-11-30
HUE046320T2 (hu) 2020-02-28
ATE511841T1 (de) 2011-06-15
US8354437B2 (en) 2013-01-15
EP1732548B1 (en) 2011-06-08
CY2012004I2 (el) 2015-10-07
JP2015157861A (ja) 2015-09-03
ES2367707T9 (es) 2012-07-05
ME01721B (me) 2014-09-20
RS53371B (sr) 2014-10-31
US20110166189A1 (en) 2011-07-07
EP2460521A1 (en) 2012-06-06
DK1732548T3 (da) 2011-09-26
DK2377536T3 (da) 2013-03-25
RS51808B9 (sr) 2019-06-28
EP2422782A1 (en) 2012-02-29
CY1111754T1 (el) 2015-10-07
CY2012004I1 (el) 2015-10-07
ES2367707T5 (es) 2024-04-25

Similar Documents

Publication Publication Date Title
FI1732548T4 (fi) Viivästetysti lääkeainetta vapauttavien aminopyridiiniyhdisteiden käyttömenetelmät
WO2008006715A3 (en) Improvements relating to pharmaceutical compositions
EP1740156B8 (de) Verfahren zur herstellung einer gegen missbrauch gesicherten, festen darreinchungsform
NZ599523A (en) Hybrid block copolymer micelles with mixed stereochemistry for encapsulation of hydrophobic agents
MX2010001839A (es) Metodo y aparato para comunicacion y metodo y aparato para controlar comunicacion.
WO2005069933A3 (en) Methods of treating an inflammatory-related disease
WO2008024435A3 (en) Dendritic molecular intracellular transporters and methods of making and using same
MX2010002100A (es) Composiciones de liposomas para administracion in vivo de compuestos de acido boronico.
WO2003037314A3 (en) Medical compositions for intravesical treatment of bladder cancer
WO2011021864A3 (ko) 신규한 항암제 보조용 화합물, 이의 제조방법, 이를 포함하는 항암제 보조용 조성물 및 이를 이용한 항암제에 대한 내성을 감소시키는 방법
WO2011128911A3 (en) Improved process for ll-[(z)-3-(dimethylamino)propyiidenel-6-ll- dihydrodibenz[b,el oxepin-2-aceticacid
WO2005070466A3 (en) Liposome composition for delivery of therapeutic agents
WO2013032558A4 (en) Products for anti-inflammation support
WO2009051417A3 (en) Phenanthrene lactam derivatives having anticancer activity and method for the preparation thereof
GR1004431B (el) Μεθοδοσαπαρασκευησαπροιοντωναμεαβασηατοακρεαςαμεααμεσηαήαμηαενσωματωσηαελαιολαδουακαιαπροσθηκηατυριουατυπουαφετα
WO2007080324A3 (fr) Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.
WO2004069180A3 (en) Solid dispersion compositions
EP2371379A3 (en) New formulation for increasing bioavailability of neurturin
WO2005077941A3 (en) Candesartan cilexetil polymorphs
WO2004069145A3 (en) Anticancer compounds, process for their preparation and pharmaceutical compositions containing them
WO2005040113A8 (en) Processes for the preparation of a polymorph of fluvastatin sodium
WO2009124950A3 (en) 4-methyl-4,5-dihydro-1h-pyrazole-3-carboxamide useful as a cannabinoid cb1 neutral antagonist
WO2006124033A3 (en) Compositions and methods for reduction of cutaneous photoageing
WO2008039894A3 (en) Atorvastatin pharmaceutical compositions
WO2009065130A3 (en) Modified release formulations of diltiazem